Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses

European Journal of Immunology

Volumn 32, Issue 12, 2002, Pages 3617-3627

  Taraban, Vadim Y ^a   Rowley, Tania F ^a   O'Brien, Lyn ^a   Claude Chan, H T ^a   Haswell, Linsey E ^a   Green, Michael H A ^a   Tutt, Alison L ^a   Glennie, Martin J ^a   Al Shamkhani, Aymen ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Costimulation; Immunotherapy; T cell activation; Tumor immunity

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CORRELATION FUNCTION; IMMUNOSTIMULATION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 0036909587     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200212)32:12<3617::AID-IMMU3617>3.0.CO;2-M     Document Type: Article

References (36)

1. Lenschow, D. J., Walunas, T. L. and Bluestone, J. A., CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 1996. 14: 233-258.
2. Shahinian, A., Pfeffer, K., Lee, K. P., Kundig, T. M., Kishihara, K., Wakeham, A., Kawai, K., Ohashi, P. S., Thompson, C. B. and Mak, T. W., Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993. 261: 609-612.
3. Viola, A., Schroeder, S., Sakakibara, Y. and Lanzavecchia, A., T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 1999. 283: 680-682.
4. Mittrucker, H. W., Shahinian, A., Bouchard, D., Kundig, T. M. and Mak, T. W., Induction of unresponsiveness and impaired T cell expansion by staphylococcal enterotoxin B in CD28-deficient mice. J. Exp. Med. 1996. 183: 2481-2488.
5. Kawai, K., Shahinian, A., Mak, T. W. and Ohashi, P. S., Skin allograft rejection in CD28-deficient mice. Transplantation 1996. 61: 352-355.
6. Wen, T., Kono, K., Shahinian, A., Kiessling, R., Mak, T. W. and Klein, G., CD28 is not required for rejection of unmanipulated syngeneic and autologous tumors. Eur J. Immunol. 1997. 27: 1988-1993.
7. Akiba, H., Oshima, H., Takeda, K., Atsuta, M., Nakano, H., Nakajima, A., Nohara, C., Yagita, H. and Okumura, K., CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. J. Immunol. 1999. 162: 7058-7066.
8. Durkop, H., Latza, U., Himmelreich, P. and Stein, H., Expression of the human OX40 (hOX40) antigen in normal and neoplastic tissues. Br. J. Haematol. 1995. 91: 927-931.
9. Al-Shamkhani, A., Birkeland, M. L., Puklavec, M., Brown, M. H., James, W. and Barclay, A. N., OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur. J. Immunol. 1996. 26: 1695-1699.
10. Al-Shamkhani, A., Mallett, S., Brown, M. H., James, W. and Barclay, A. N., Affinity and kinetics of the interaction between soluble trimeric OX40 ligand, a member of the tumor necrosis factor superfamily, and its receptor OX40 on activated T cells. J. Biol. Chem. 1997. 272: 5275-5282.
11. Chen, A. I., McAdam, A. J., Buhlmann, J. E., Scott, S., Lupher, M. L., Jr., Greenfield, E. A., Baum, P. R., Fanslow, W. C., Calderhead, D. M., Freeman, G. J. and Sharpe, A. H., Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity 1999. 11: 689-698.
12. Murata, K., Ishii, N., Takano, H., Miura, S., Ndhiovu, L. C., Nose, M., Noda, T. and Sugamura, K., Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J. Exp. Med. 2000.191: 365-374.
13. Kopf, M., Ruedl, C., Schmitz, N., Gallimore, A., Lefrang, K., Ecabert, B., Odermatt, B. and Bachmann, M. F., OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL responses after virus infection. Immunity 1999. 11: 699-708.
14. Gramaglia, I., Jember, A., Pippig, S. D., Weinberg, A. D., Killeen, N. and Croft, M., The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J. Immunol. 2000. 165: 3043-3050.
15. Maxwell, J. R., Weinberg, A., Prell, R. A. and Vella, A. T., Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J. Immunol. 2000. 164: 107-112.
16. Shuford, W. W., Klussman, K., Tritchler, D. D., Loo, D. T., Chalupny, J., Siadak, A. W., Brown, T. J., Emswiler, J., Raecho, H., Larsen, C. P., Pearson, T. C., Ledbetter, J. A., Aruffo, A. and Mittler, R. S., 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 1997. 186: 47-55.
17. Cannons, J. L., Lau, P., Ghumman, B., DeBenedette, M. A., Yagita, H., Okumura, K. and Watts, T. H., 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J. Immunol. 2001. 167: 1313-1324.
18. Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellstrom, K. E., Mittler, R. S. and Chen, L., Monoclonal antibodies against the 4-1BB T cell activation molecule eradicate established tumors. Nat. Med. 1997. 3: 682-685.
19. Kim, J. A., Averbook, B. J., Chambers, K., Rothchild, K., Kjaergaard, J., Papay, R. and Shu, S., Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T cell generation. Cancer Res. 2001. 61: 2031-2037.
20. DeBenedette, M. A., Wen, T., Bachmann, M. F., Ohashi, P. S., Barber, B. H., Stocking, K. L., Peschon, J. J. and Watts, T. H., Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J. Immunol. 1999. 163: 4833-4841.
21. Weinberg, A. D., Rivera, M. M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J., Alvord, G., Bunce, C. and Shields, J., Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 2000. 164: 2160-2169.
22. Kjaergaard, J., Tanaka, J., Kim, J. A., Rothchild, K., Weinberg, A. and Shu, S., Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 2000. 60: 5514-5521.
23. Williams, L. M., Gibbons, D. L., Gearing, A., Maini, R. N., Feldmann, M. and Brennan, F. M., Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF α-processing in RA synovial membrane cell cultures. J. Clin. Invest. 1996. 97: 2833-2841.
24. Hansen, H. P., Dietrich, S., Kisseleva, T., Mokros, T., Mentlein, R., Lange, H. H., Murphy, G. and Lemke, H., CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-α-converting enzyme. J. Immunol. 2000. 165: 6703-6709.
25. Solorzano, C. C., Ksontini, R., Pruitt, J. H., Hess, P. J., Edwards, P. D., Kaibara, A., Abouhamze, A., Auffenberg, T., Galardy, R. E., Vauthey, J. N., Copeland, E. M., 3rd, Edwards, C. K., 3rd, Lauwers, G. Y., Clare-Salzler, M., MacKay, S. L., Moldawer, L. L. and Lazarus, D. D., Involvement of 26-kDa cell-associated TNF-α in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J. Immunol. 1997. 158: 414-419.
26. Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J. and Carbone, F. R., T cell receptor antagonist peptides induce positive selection. Cell 1994. 76: 17-27.
27. Huang, A. Y., Gulden, P. H., Woods, A. S., Thomas, M. C., Tong, C. D., Wang, W., Engelhard, V. H., Pasternack, G., Cotter, R., Hunt, D., Pardoll, D. M. and Jaffee, E. M., The immuno-dominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA 1996. 93: 9730-9735.
28. Tutt, A. L., O'Brien, L., Hussain, A., Crowther, G. R., French, R. R. and Glennie, M. J., T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J. Immunol. 2002. 168: 2720-2728.
29. Bansal-Pakala, P., Jember, A. G. and Croft, M., Signaling through OX40 (CD134) breaks peripheral T cell tolerance. Nat. Med. 2001. 7: 907-912.
30. Gramaglia, I., Weinberg, A. D., Lemon, M. and Croft, M., Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 1998. 161: 6510-6517.
31. Taylor, L. and Schwarz, H., Identification of a soluble OX40 isoform: development of a specific and quantitative immunoassay. J. Immunol. Methods 2001. 255: 67-72.
32. Michel, J., Langstein, J., Hofstadter, F. and Schwarz, H., A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis. Eur. J. Immunol. 1998. 28: 290-295.
33. Arch, R. H. and Thompson, C. B., 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor κB. Mol. Cell. Biol. 1998. 18: 558-565.
34. Xu, Y., Cheng, G. and Baltimore, D., Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity 1996. 5: 407-415.
35. Tsitsikov, E. N., Laouini, D., Dunn, I. F., Sannikova, T. Y., Davidson, L., Alt, F. W. and Geha, R. S., TRAR is a negative regulator of TNF signaling. enhanced TNF signaling in TRAF1-deficient mice. Immunity 2001. 15: 647-657.
36. DeBenedette, M. A., Shahinian, A., Mak, T. W. and Watts, T. H., Costimulation of CD28- T lymphocytes by 4-1BB ligand. J. Immunol. 1997. 158: 551-559.